Natural plant products in treatment of pulmonary arterial hypertension

Lili Xiang¹, Ying Li²,³, Xu Deng⁴, Djuro Kosanovic⁵, Ralph Theo Schermuly⁵ and Xiaohui Li¹,³
¹Department of Pharmacology, School of Pharmaceutical Sciences, Central South University, Changsha, China; ²Department of Health Management, The Third Xiangya Hospital, Central South University, Changsha, China; ³Hunan Key Laboratory for Bioanalysis of Complex Matrix Samples, Changsha, China; ⁴Department of Pharmaceutical Chemistry, School of Pharmaceutical Sciences, Central South University, Changsha, China; ⁵Universities of Giessen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research, Giessen, Germany

Abstract
Pulmonary arterial hypertension (PAH) is a severe disease characterized by progressive remodeling of distal pulmonary arteries and persistent elevation of pulmonary vascular resistance (PVR), which leads to right ventricular dysfunction, heart failure, and eventually death. Although treatment responsiveness for this disease is improving, it continues to be a life-threatening condition. With the clinical efficacy of natural plant products being fully confirmed by years of practice, more and more recognition and attention have been obtained from the international pharmaceutical industry. Moreover, studies over the past decades have demonstrated that drugs derived from natural plants show unique advantages and broad application prospects in PAH treatment, not to mention the historical application of Chinese traditional medicine in cardiopulmonary diseases. In this review, we focus on summarizing natural plant compounds with therapeutic properties in PAH, according to the extracts, fractions, and pure compounds from plants into categories, hoping it to be helpful for basic research and clinical application.

Keywords
pulmonary arterial hypertension, natural products, traditional Chinese medicine, treatment, pulmonary vascular resistance

Date received: 1 November 2017; accepted: 30 May 2018

Pulmonary Circulation 2018; 8(3) 1–20
DOI: 10.1177/2045894018784033

Pulmonary arterial hypertension (PAH) is a severe disease characterized by progressive pulmonary vascular remodeling and an increase in pulmonary vascular resistance (PVR), which may lead to right ventricular dysfunction, heart failure, and death. In addition, the prognosis of PAH is still poor and the mortality rate is highly comparable to cancer. Although treatment strategies for this pulmonary vascular disease are improving, it still represents a life-threatening disorder.

There are several drugs available in clinic, such as inhaled nitric oxide (NO), prostacyclin drugs, endothelin receptor antagonists, Phosphodiesterase type 5 inhibitor, and the latest developed soluble guanylate cyclase stimulator. Unfortunately, current therapeutics for PAH are limited; most are designed to reduce pulmonary arterial resistance by inducing vasodilation. The progressive vascular remodeling is still hardly to be reversed. Thus, there is an urgent need for novel therapies.

Historically, natural products from plants and animals were the source of virtually all medicinal preparations. More recently, natural products have been developed as new medicines in clinical practice after convincing clinical trials, particularly as vascular disease treatment agents. Furthermore, the utilization of natural products or natural product structures plays an extremely significant role in the treatment of PAH.
## Table 1. Natural plants for any vascular disease.

| Vascular disease                  | Natural plants                        | Efficacy                                                                                                                                                                                                 | Reference |
|-----------------------------------|---------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| Atherosclerosis                   | Ginkgo biloba leaf                    | • Reduce atherosclerotic nanoplaque formation and size, suppress atherosclerotic lesion development  
  • Reduce intima-media ratio, decrease proliferation and migration of VSMCs, and induce greater apoptosis  
  • Improve glucose homeostasis and circulating adiponectin levels, attenuate the expression of connexin 43 protein and the concentrations of plasma Homo sapiens C-reactive protein | 146–147   |
|                                  | Salvia miltiorrhiza Bunge              | • Inhibit atherosclerotic lesion formation in aorta  
  • Lower cholesterol and inhibit low density lipoprotein oxidative modification  
  • Downregulate protein expression and activities of matrix metalloproteinase-2 and matrix metalloproteinase-9 through inhibiting nicotinamide adenine dinucleotide phosphate oxidase 4-mediated reactive oxygen species generation | 148–151   |
|                                  | Green tea                             | • Protect apolipoprotein E−/− mice from atherosclerosis through the Jagged 1/Notch pathway  
  • Attenuates atherosclerotic lesion formation and development through decreasing macrophage cholesterol content and MCP-1 expression in macrophages  
  • Reduce total cholesterol, triglycerides, low-density and very low-density lipoprotein cholesterol fractions, and increase high-density lipoprotein | 152–154   |
|                                  | Astragalus membranaceous              | • Alleviate the extent of atherosclerosis in aorta of apolipoprotein E−/− mice  
  • Suppress the progression of atherosclerotic lesions and the inflammatory reaction  
  • Reduce plasma levels of total cholesterol and low-density lipoprotein cholesterol, increase high density lipoprotein cholesterol levels, and reduce the aortic fatty streak area | 155–157   |
| Thrombus and platelet aggregation | Ginkgo biloba leaf                    | • Inhibit platelet aggregation induced by oxidative stress, platelet activation factor, or collagen  
  • Reduce the plasma levels of thromboxane B2 and prostacyclin metabolites  
  • Inhibit the production of cyclooxygenase-1-mediated thromboxaneA2 in platelets and cyclooxygenase-2-mediated prostaglandin I2 in endothelial cells non-selectively | 158,159   |
|                                  | Salvia miltiorrhiza Bunge              | • Inhibits thrombosis formation, platelet aggregation  
  • Inhibits platelet adhesion to immobilized collagen by interfering with the collagen receptor α2β1  
  • Suppress [Ca^{2+}] mobilization and arachidonic acid liberation | 160–165   |
|                                  | Uncaria rhynchophylla                 | • Inhibit platelet aggregation and antithrombotic  
  • Reduce the thromboxane B2 generation in platelet rich plasma induced by collagen  
  • Suppress the formation of malondialdehyde in platelet suspension stimulated by thrombin and inhibit the release of platelet factor 4 | 166–168   |
|                                  | Anemarrhena asphodeloides             | • Inhibit platelet aggregation, blood coagulation, as well as the formation of a thrombus  
  • Delay the activated time of thromboplastin  
  • Antiplatelet and anticoagulation | 169,170   |
|                                  | Panax notoginseng                     | • Inhibit platelet aggregation and plasma coagulation  
  • Suppress thrombin-induced platelet superficial activation and adhesion in vitro and improve hypercoagulable state in vivo  
  • Over-express peroxisome proliferator-activated receptor γ protein and mRNA and upregulate phosphatidylinositol 3 kinase/protein kinase B through endothelial NOS pathway in platelet | 171–173   |
| Vascular disease | Natural plants | Efficacy                                                                                                                                                                                                                                                                                                                                 | Reference |
|------------------|----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| Hypertension     | Ginkgo biloba leaf | • Protect against hypertension with hypercholesterolemia-induced renal injury  
• Reduce vasospasm and increase relaxation  
• Suppress renal oxidative stress, nitrosative stress, and inflammation  
|                   |                |                                                                                                                                                                                                                                                                                                                                       | 174–176   |
|                  | Salvia miltiorrhiza Bunge | • Lower arterial blood pressure under basal conditions in spontaneously hypertensive rat models and relax coronary arteries in a cumulative dose-dependent manner  
• Decreased the average blood flow velocity in liver in ET-1 induced portal hypertension  
• Improve cardiac function and reduce arterial blood pressure partially via inhibiting nicotinamide adenine dinucleotide phosphate oxidase and activating the nitric oxide signaling pathway  
|                   |                |                                                                                                                                                                                                                                                                                                                                       | 177–179   |
|                  | Uncaria rhynchophylla | • Anti-hypertensive, anti-arrhythmic, anti-thrombotic and inhibit platelet aggregation  
• Lower the blood pressure, improve the structural integrity of vascular endothelium  
• Decrease the expression of intercellular adhesion molecule 1 and selectin P, block the release of calcium from intracellular stores  
|                   |                |                                                                                                                                                                                                                                                                                                                                       | 180–184   |
|                  | Ligusticum wallichii Rhizome | • Elicit an effect on vasorelaxation in isolated rat aortas and anti-hypertension in spontaneously hypertensive rat  
• Reduce portal pressure in portal hypertensive rats  
| Ischemia-reperfusion injury | Ginkgo biloba leaf | • Protect against myocardium ischemic/reperfusion injury by decreasing oxidative stress, repressing inflammatory cascade in vivo, and inhibiting toll-like receptor 4/nuclear factor kappa B pathway in rat model  
• Suppress renal epithelial tubular cell apoptosis  
• Decrease NO production by inhibiting gene and protein expression and enzymatic activity of inducible NOS  
|                   |                |                                                                                                                                                                                                                                                                                                                                       | 187–190   |
|                  | Salvia miltiorrhiza Bunge | • Prevent cardiac ischemic/reperfusion injury and improve cardiac function in a rat model of hypertrophy  
• Protect against neonatal hypoxia-ischemia brain injury in vivo by an increase in the ratio of Bcl-2 to Bax expression  
• Protect the mitochondrial membrane from the ischemia-reperfusion injury and lipid peroxidation through an electron transfer reaction in mitochondria against forming reactive oxygen radicals  
|                   |                |                                                                                                                                                                                                                                                                                                                                       | 191–193   |
|                  | Uncaria rhynchophylla | • Protect against cerebral ischemia/reperfusion damage  
• Significantly reduce infarct volume and improve neurological function after ischemic brain injury through the inhibition of lipopolysaccharide-stimulated production of pro-inflammatory cytokines  
• Reduce the lipid peroxidation injury of brain cells through inhibiting the NOS activity and increasing the superoxide dismutase activity  
|                   |                |                                                                                                                                                                                                                                                                                                                                       | 194,195   |
|                  | Ligusticum wallichii Rhizome | • Suppress ischemia-induced ventricular arrhythmias and reduce the infarct size resulting from ischemia/reperfusion injury  
• Enhance myocardial antioxidant status through induction of heme oxygenase-1 and inhibition of neutrophil and improve the immunity profile in ischemic-reperfusion rats  
• Protect cells against glutamate-induced apoptosis via the inhibition of oxidative stress and a change in the levels of apoptosis-related proteins, Bcl-2 and Bax  
|                   |                |                                                                                                                                                                                                                                                                                                                                       | 196–199   |

(continued)
role in the drug discovery and development process. A detailed analysis of new medicines approved by the U.S. Food and Drug Administration during 1981–2010 revealed that 34% of those medicines based on small molecules were natural products or direct derivatives of natural products, including the stains, tubulin-binding anticancer drugs, and immunosuppressants.11,12 Furthermore, because of the increasing high cost and lengthy development process of chemical drugs, the natural products industry, characterized by “naturopathy,” is thought to become the most promising industry in the global pharmaceutical industry. Interestingly, studies over the past decades have demonstrated that drugs derived from natural plants show unique advantages and broad application prospects in PAH treatment, not to mention the historical application of traditional Chinese medicine (TCM) in cardiopulmonary diseases. Experimental and clinical research revealed that natural products can ameliorate the symptoms and improve prognosis of PAH. Additionally, some natural products selectively improve the pulmonary circulation without affecting systemic arterial pressure. In this review, we will summarize the current knowledge about the natural plant compounds with the potential and promising therapeutic properties in the field of PAH, according to the extracts, fractions, and pure compounds from plants into categories, hoping it will provide useful information for future basic research and clinical application (Table 2).

**Alkaloids**

Alkaloids are a group of alkaline nitrogenous natural products, which are widely distributed in plants and usually exhibit a broad range of pharmacological activities including anti-tumor, anti-inflammatory, anti-viral, and analgesic.13–15 Many of them have been used in traditional and modern drug development.

**Ligustrazine**

Ligustrazine, also known as tetramethylpyazine, is an effective constituent of *Scechwan Lovage Rhizome*. It also exists in the rhizome of *Curcuma aromatica Salisb* and *Jatropha podagrica Hook*. Studies have shown that ligustrazine can significantly reduce mean pulmonary arterial pressure (mPAP), PVR, and the plasma endothelin-1 (ET-1) levels in acute hypoxia-induced pulmonary hypertension (PH) dogs;16 and meanwhile upregulate NO levels in patients with PAH, through alleviating the damage of pulmonary arterial endothelial cells (PAECs) and restoring the balance between vasoactive factors.17

There are several possible contributions to the function of ligustrazine. It is revealed that ligustrazine can inhibit platelet aggregation and prevent thrombosis effectively.18,19 It has also been discovered that ligustrazine can block the release of reactive oxygen species from lung tissue20 and moderate the upregulation of hypoxia-inducible factor 1 and vascular endothelial growth factor (VEGF) expression, which consequently reduces hypoxia-induced lung injury.21 Also, ligustrazine is a Ca$^{2+}$ channel antagonist which can dilate the blood vessels during hypoxia by blocking Ca$^{2+}$ influx.22,23 This may be one of the principal mechanisms responsible for the protective effect of ligustrazine in patients with PAH.

**Tetrandrine**

Tetrandrine (TET) is a bisbenzylisoquinoline alkaloid extracted from the root of *Stephania tetrandra S. Moore*. It also existed in the stem of *Menispernum dauricum DC*, the root of *Stephania cepharantha Hayata*, and *Cyclea barbata (Wall.) Miers*. Xie et al. and Wei et al. found that TET produces multiple pharmacological effects, for instance, protecting myocardial, cerebral, and renal ischemia.24,25 Remarkably, it also helps to prevent hypoxic PH.

In 2010, Feng et al. reported that TET selectively ameliorated monocrotaline (MCT)-induced PAH in rats by reducing PVR and right ventricular hypertrophy (RVH) without affecting the systemic pressure, thus significantly reversing the damage of pulmonary vascular and lung tissue,26 which merits TET as a candidate for PAH treatment. Furthermore, in 2014, Feng et al. demonstrated that TET could reverse the elevation of mPAP and the remodeling of small pulmonary arteries, induced by MCT.27 TET acts as an antagonist of some vasoconstriction factors such as platelet-activating factor, angiotensin II, and prostaglandin F, which play a significant role in the occurrence and development of PAH. Studies have demonstrated that TET could directly downregulate the expression of...
| Category | Natural products | Origin | Efficacy | Mechanism | Subjects | Reference |
|----------|-----------------|--------|----------|-----------|----------|-----------|
| Alkaloids | Ligustrazine     | *Ligusticum wallichii* Rhizome; *Curcuma aromatica* Salisb; *Jatropha podagrica* Hook | Decrease plasma ET-1 level, reduce mPAP and PVR | Enhance the synthesis and release of NO and suppress those of ET-1; decrease mPAP, internal diameter of right ventricle, and outflow of right ventricle | Dog | 16 |
|          |                 |        | Attenuate the plate aggregation, reduce thrombus formation and blood viscosity, accelerate blood flow restoration | Inhibit the platelet aggregation formation and thrombus | Human | 17 |
|          |                 |        | Inhibit the platelet aggregation formation and thrombus | Inhibit platelet activation | Rat | 18 |
|          | Tetrandrine     | *Stephania tetrandra* S.Moore; *Cyclaea barbata* (Wall.) Miers; *Menispernum dauricum* DC | Inhibit PASMCs proliferation, improve endothelial function; reduce mPAP and RVH index; reverse pulmonary vascular remodeling and attenuate oxidation in lung | Inhibit the activity of serum angiotensin enzyme, decrease the amount of angiotensin I converted to angiotensin II, suppress the proliferation of medullar collagen and PASMCs in pulmonary acinar artery, reduce pulmonary vasoconstriction and lower PH | Rat | 19 |
|          |                 |        | Adjust the imbalance of the NO signaling pathway and change the expression of inducible NOS and cyclic guanosine monophosphate-dependent protein kinase-I. | TET is a calcium antagonist that blocks the influx of calcium from vascular smooth muscle, relaxes vascular smooth muscle; it also decreases the content of prostaglandin F2 in the lung, so as to reduce the contractility of the pulmonary vasculature and thus reduce the PH | 27,30 |
| Flavonoids | Ginkgo biloba extracts | *Ginkgo biloba* | Relieve RVH and reduce chronic hypoxic PH | Attenuate the function of PKC signal channel | Rat | 26,28,29,31 |
|          |                 |        | Antagonize platelet activating factor, angiotensin and reduce blood viscosity | Inhibit the deposition of collagen | Rat | 32 |
|          | Puerarin        | *Puerarin lobat* (Willd) Ohwi | Inhibit pulmonary vascular remodeling, RVH, and PH | | | 40 |
|          |                 |        | | | | 41 |
|          |                 |        | | | | 47 |
| Category | Natural products | Origin | Efficacy | Mechanism | Subjects | Reference |
|----------|------------------|--------|----------|-----------|----------|-----------|
| Glycosides | Salidroside | *Rhodiola rosea* L | Reduce mitochondrial membrane potential, cytochrome C release and caspase-9 activation, inhibit cell growth and apoptosis | Downregulated the expression of elongation factor 2 | Rat | 48 |
| | | | | | Human | 49 |
| | | | | | Rat | 56 |
| | | | | | Human | 57 |
| | | | | | Rat | 58 |
| | | | | | Mice | 60 |
| | | | | | Rat PASMCs | 61 |
| | | | | | Rabbit | 62 |
| | | | | | Rat | 63,64 |
| | | | | | Pig | 69 |
| | | | | | Rat | 70 |
| | | | | | Rat | 87 |

(continued)
| Category   | Natural products | Origin                        | Efficacy                                                                                      | Mechanism                                                                                                                | Subjects | Reference |
|------------|------------------|-------------------------------|-----------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------|----------|-----------|
| Diterpenoids | Tanshinone IIA   | *Salvia miltiorrhiza* Bge; *Salvia sclarea* L; *Salvia przewalskii* Maxim | Recover acute hypoxia-induced down-regulation of $I_{Kv}$ currents and upregulate the mRNA and protein expression of $Kv$ 1.5 and $Kv$ 2.1 in PASMCs, reduce right ventricular systolic pressure and RVH, and restrain pulmonary wall remodeling | Reverse the $I_{Kv}$ currents through modulating the expression of $Kv$ channels in pulmonary arterioles | Rat      | 91        |
|            | Sodium Tanshinone IIA sulfonate |                          | Decrease right ventricular systolic PAP and RVH, attenuate medial wall thickening, PVR and remodeling | Inhibit increase of transient receptor potential superfamily members 1,6 and decrease SOCE through reducing the numbers or activity of SOCC and basal $[Ca^{2+}]_i$ |                                    | 95        |

(continued)
| Category | Natural products | Origin | Efficacy | Mechanism | Subjects | Reference |
|----------|-----------------|--------|----------|-----------|----------|-----------|
| **Reduce pulmonary artery systolic pressure and Borg dyspnea score, improve exercise capacity, and decrease WHO FC of PH from III or IV down to II** | **Triptolide** | *Tripterygium wilfordii Hook. F.* | Promote the regression of pulmonary artery neointimal formation, attenuate the development of RVH, pulmonary remodeling, and PH | Antiproliferation and anti-inflammatory effects or enhancement of apoptosis in PAECs | **Rat** | 99 |
| **Promote the regression of pulmonary artery neointimal formation, attenuate the development of RVH, pulmonary remodeling, and PH** | **Triptolide** | *Tripterygium wilfordii Hook. F.* | Promote the regression of pulmonary artery neointimal formation, attenuate the development of RVH, pulmonary remodeling, and PH | Antiproliferation and anti-inflammatory effects or enhancement of apoptosis in PAECs | **Rat** | 99 |
| **Inhibit the activity of matrix metalloproteinases** | **Pyanocoumarins** | Praeruptorin A | Inhibit PASMC proliferation and attenuate PH | Inhibit the activity of matrix metalloproteinases | **Rat** | 100,101 |
| **Effect the balance of matrix metalloproteinase 9/tissue inhibitor of metalloproteinase** | **Pyanocoumarins** | Praeruptorin A | Inhibit PASMC proliferation and attenuate PH | Inhibit the activity of matrix metalloproteinases | **Rat** | 102 |
| **Inhibit chronically hypoxic enhancement of basal [Ca\(^{2+}\)]\(_i\) and SOCE** | **Pyanocoumarins** | Praeruptorin A | Inhibit chronically hypoxic enhancement of basal [Ca\(^{2+}\)]\(_i\) and SOCE | Inhibit hypoxia caused Kv1.5 and Kv2.1 mRNA expression down, maintain cell membrane potential balance | **Rat** | 114 |
| **Inhibit hypoxia caused Kv1.5 and Kv2.1 mRNA expression down, maintain cell membrane potential balance** | **Stilbenes** | Resveratrol | Prevent hypoxia-induced human PASMC proliferation, attenuate RVH | Induct the serine threonine kinase 1-dependent inhibition of arginase II. | **Human** | 117 |
| **Induct the serine threonine kinase 1-dependent inhibition of arginase II.** | **Stilbenes** | Resveratrol | Prevent hypoxia-induced human PASMC proliferation, attenuate RVH | Induct the serine threonine kinase 1-dependent inhibition of arginase II. | **Human** | 122 |
| **Attenuate oxidative stress and inhibit inflammatory reaction, improve the function of PAECs, reverse the right ventricle and pulmonary artery reconstruction** | **Stilbenes** | Resveratrol | Prevent hypoxia-induced human PASMC proliferation, attenuate RVH | Induct the serine threonine kinase 1-dependent inhibition of arginase II. | **Rat** | 123 |
| **Reduce mPAP and PH** | **Stilbenes** | Resveratrol | Prevent hypoxia-induced human PASMC proliferation, attenuate RVH | Induct the serine threonine kinase 1-dependent inhibition of arginase II. | **Rat** | 127 |
| **Suppress the expression of MCP-1 and p- p38-mitogen-activated protein kinase expression** | **Others** | Semen lepidii | Enhance myocardial contractility, reduce PH | Enhance myocardial contractility, reduce PH | **Human** | 129 |
| **Enhance myocardial contractility, reduce PH** | **Others** | Semen lepidii | Enhance myocardial contractility, reduce PH | Enhance myocardial contractility, reduce PH | **Human** | 130 |
| **Increase partial pressure of O\(_2\) and decrease partial pressure of CO\(_2\), reduce mPAP and PVR** | **Others** | Semen lepidii | Enhance myocardial contractility, reduce PH | Enhance myocardial contractility, reduce PH | **Human** | 130 |
| **Reduce right ventricular systolic and diastolic blood pressure and mPAP** | **Others** | Semen lepidii | Enhance myocardial contractility, reduce PH | Enhance myocardial contractility, reduce PH | **Rat** | 131 |
| **Reduce mPAP and PH** | **Others** | Semen lepidii | Enhance myocardial contractility, reduce PH | Enhance myocardial contractility, reduce PH | **Rat** | 132 |
| Category      | Natural products                                      | Origin                                                                 | Efficacy                                                                                                                                                                                                 | Mechanism                                                                                                                                                                                                 | Subjects | Reference |
|---------------|-------------------------------------------------------|------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------|-----------|
| Radix Astragali | *Astragalus membranaceus* (Fisch) Bge.; *Astragalus membranaceus* (Fisch) Bge. var. Mongholicus (Bge.) Hsiao | Inhibit proliferation of adventitial cells, hypertrophic of tunica media, muscularization of non-muscular arteries and the structural remodeling of intra-acinar pulmonary arteries and PH | Preserve the endothelial cells, dilate the pulmonary circulation, and improve hemodynamic condition                                                                 | Rat                                                                                                                                         | 134      |           |
|               |                                                       | Preserve intra-acinar pulmonary arteries wall cells proliferation, dilate pulmonary artery, inhibit intra-acinar pulmonary arteries remodeling, and improve PH | Regulate the concentration of ET-1 and NO in pulmonary tissue, reverse the reconstruction of pulmonary vessels partially                                                                 | 135                                                                                                                                         |          |           |
|               |                                                       | Regulate the concentration of ET-1 and NO in pulmonary tissue, reverse the reconstruction of pulmonary vessels partially | Decrease the concentration of thromboxane A2 and reverse the remodeling of pulmonary artery partly                                                                 | 136, 137                                                                                                                                                                                                         |          |           |
|               |                                                       | Regulate the concentration of superoxide dismutase and oxygen free radicals in pulmonary tissue | Protect pulmonary vascular from hypoxia by anti-oxidant effects                                                                 | 138                                                                                                                                         |          |           |
|               |                                                       | Eliminate oxygen free radicals and reduce blood viscosity               | Regulate the concentration of superoxide dismutase and oxygen free radicals in pulmonary tissue                                                                 | 139                                                                                                                                         |          |           |
|               |                                                       |                                                                        | Protect pulmonary vascular from hypoxia by anti-oxidant effects                                                                 | 139                                                                                                                                         |          |           |

AMPK, adenosine monophosphate-activated protein kinase; Bcl-2, B cell leukemia/lymphoma 2; Bax, Bcl-2-associated protein x; ET-1, endothelin-1; FC, functional class; Kv, voltage-gated K⁺; MCT, monocrotaline; mPAP, mean pulmonary arterial pressure; NO, nitric oxide; PAEC, pulmonary arterial endothelial cell; PAH, pulmonary arterial hypertension; PH, pulmonary hypertension; PASMC, pulmonary artery smooth muscle cell; PKC, protein kinase C; PVR, pulmonary vascular resistance; RVH, right ventricular hypertrophy; SOCC, store-operated calcium channel; SOCE, SOCC-mediated store-operated Ca²⁺ entry; TET, Tetrandrine; WHO, World Health Organization.
platelet-derived growth factor and basic fibroblast growth factor in rats with PAH, thus inhibiting vascular smooth muscle cell (VSMC) proliferation, relieving pulmonary vascular remodeling, and consequently attenuating the development of PAH. Furthermore, TET improves the function of PAECs and remits mPAP by attenuating the expression of inducible nitric oxide synthase (NOS) and upregulating the expression of protein kinase 1 in the lung tissue of PAH rats. TET also increases the activity of superoxide dismutase in lung tissue, accelerates the scavenging of oxygen free radicals, and prevents the impairing of lung function cells. It is generally accepted that hypoxic vasoconstriction can be inhibited by Ca^{2+} channel blockers via blood vessels dilatation. TET is thought to be a weaker calcium channel antagonists and studies have suggested that TET can turn down Ca^{2+} influx by blocking Ca^{2+} channels, which partly contributes to the protective effect of TET in PAH.

**Flavonoids**

Flavonoids are widely distributed in plants and berries, such as *Ginkgo biloba Linn*, *Pueraria lobata*, *Crataegus pinnatifida*, and *Vitis vinifera*. Modern pharmacological studies have revealed that these compounds possess obvious pharmacological effects in the cardiovascular and endocrine system. Many preparations have been utilized as medicines, such as puerarin-based Yufeng Ningxin tablets and ginkgo preparations of Tianbao Ning.

**Ginkgo biloba extracts**

Nowadays, Ginkgo biloba extracts (GBEs) are widely used in treating cardiovascular diseases for their outstanding pharmacological effects. The main active components of GBEs are flavonoids and diterpenoids. Ginkgo biloba flavonoids have strong anti-oxidation and free-radical scavenging effects. Diterpenoids, such as Ginkgolide B, can also reduce the generation of free radicals.

Also, GBEs exert promising effects on improving acute lung injury (ALI) via downregulating the c-Jun N-terminal kinase and protein kinase B-dependent nuclear factor κB activation pathway. Moreover, they inhibit platelet activation and aggregation induced by platelet factors and therefore have the potential to improve blood circulation.

Studies have shown that Ginkgo biloba can reduce chronic hypoxic PH and relieve RVH, which is partly related to the attenuation of the function of the protein kinase C (PKC) signal channel. It is also reported that Ginkgo Plus significantly reduces the hypoxia-induced increase of mPAP and PVR as well as the ratio of right ventricular weight vs. left ventricular plus septal weights. GBEs alleviate the apoptosis of endothelial cells (ECs) caused by hydrogen peroxide. In addition, they stabilize inflammatory cells and show anti-inflammatory effect by decreasing the release of inflammatory mediators. Furthermore, GBEs may decrease the concentration of NO and increase superoxide dismutase activity in plasma accompanied by the downregulation of inducible NOS expression. Consequently, GBEs indirectly decrease the injury of pulmonary vascular ECs and improve PAH.

**Puerarin**

Puerarin is isolated from the dried roots of *Pueraria lobata* (Willd.) Ohwi. It dilates blood vessels, decreases myocardial oxygen consumption, and improves myocardial ischemia. Recently, Li et al. observed that puerarin could improve pulmonary vascular remodeling in rats with PH by inhibiting the deposition of collagen. A study also showed that puerarin exerted protective effects in MCT-induced PAH rats. Furthermore, puerarin can induce the release of cytochrome C, activate caspase-9, downregulate B cell leukemia/lymphoma 2 (Bcl-2), and upregulate Bcl-2-associated protein x (Bax) expression. It can scavenge oxygen free radicals and inhibit the proliferation of smooth muscle cells (SMCs). Studies have also confirmed that puerarin induces human pulmonary artery smooth muscle cells (PASMCs) apoptosis via a mitochondria-dependent pathway.

**Glycosides**

Many Chinese herbal medicines contain glycosides such as ginseng, liquorice, Rhodiola, Polygonum cuspidatum, etc., which are effective ingredients with powerful activities.

**Salidroside**

Medicinal plant *Rhodiola rosea* L is a kind of perennial herb; it contains salidroside, tyrosol, flavonoid compounds, amino acids, trace elements, and other ingredients. Rhodiola mainly possesses effects of anti-aging, anti-anoxia, anti-fatigue, anti-depressants, and anti-radiation. It can also enhance immunity, regulate the nervous system, and protect the cardiovascular system. Above all, Rhodiola has great therapeutic potential.

Rhodiola can significantly inhibit VSMC proliferation and contraction, and reduce the concentration of plasma ET-1 in rats with PH. It is also suggested that Rhodiola inhibits ET-1 expression and promotes the synthesis and the release of NO by affecting pulmonary vasculature selectively. Furthermore, Rhodiola can alleviate the imbalance of systolic and diastolic pulmonary arterial pressure. It also lowers mPAP, alleviates RVH, and improves PH which may be associated with the declined expression of VEGF in the pulmonary arteriolar wall. In addition, Rhodila has a notable effect on high-altitude environment-induced PH rats, and inhibition of transforming growth factor beta-1 expression is one of the possible mechanisms.

Adenosine A2a receptor, which is one of the G protein coupled receptors, shows the effects of anti-inflammation after being activated by adenosine and analogues under
physiological and pathological conditions. Moreover, studies have shown that the Salidroside, as a main pharmacological ingredient of Rhodiola, can increase the expression of Adenosine A2a receptor in PASMCs, reversing the downregulated ratio of Bax and Bcl-2 induced by hypoxia. Furthermore, it also promotes the release of mitochondrial cytochrome C into the cytoplasm, accelerates the elimination of caspase 9 via mitochondrial pathway, and thus enhances apoptosis. In addition, Salidroside can reverse the remodeling of pulmonary arterial pressure induced by chronic hypoxia and therefore alleviate the mPAP.

Also, Salidroside inhibits platelet-derived growth factor-BB-induced proliferation and DNA synthesis of PASMCs by blocking the process of G0/G1 to S phase. This may be related to decreasing the expression of cyclin D1 and increasing the accumulation of p27 by blocking the protein kinase B/glycogen synthase kinase-3β signaling pathway. In recent years, the relationship between adenosine monophosphate-activated protein kinase (AMPK) and lung disease has increasingly caught the attention of researchers. The current studies suggest that AMPK also plays a vital role in treating lung cancer, bronchial asthma, PAH, and other pulmonary diseases. Besides, Salidroside inhibits the increase of G2/M phase cells induced by hypoxia via AMPKζ1-P53-P27/P21 pathway. Accordingly, the proliferation and DNA synthesis of PASMCs are inhibited. In addition, Salidroside lowers the levels of P21 and P27, upregulates P53, and mediates apoptosis by regulating the expression of Bax and Bcl-2 via AMPKζ1-P53-Bax/Bcl-2-caspase 9-caspase 3 pathway. Consequently, the imbalance of PASMCs proliferation and apoptosis are restored, the pulmonary arterial remodeling is inhibited and the chronic hypoxia-induced PH is relieved via AMPKζ1-P53 pathway.

**Polydatin**

*Polygonum cuspidatum* Sieb. et Zucc is a TCM which is mainly used for treating chronic bronchitis, traumatic injury, and damp-heat jaundice clinically. Polydatin (PD) is the main active ingredient extracted from *Polygonum cuspidatum* Sieb. et Zucc and *Fallopia multiflora* (Thunb.) Harald with the pharmacological effects of suppressing myocardial cell contraction and platelet aggregation, anti-oxidation, and anti-shock. It is reported that PD significantly reduces PAP in hypoxic animals and it can increase cardiac output and improve fibrinolytic activity. Moreover, Miao et al. observed that PD can alleviate hypoxic PH and reverse remodeling, which attributes to a protective role in treating oxidative stress injury via PKC signaling pathway. On the one hand, PD attenuates the phosphorylation of PKCζ and δ induced by H2O2; meanwhile, it increases the phosphorylation of PKCζ which has antioxidant effects. On the other hand, PD alleviates lung injury through inducing apoptosis and inhibiting proliferation by depressing the cell cycle, upregulating Bax, and downregulating Bcl-2. However, the exact mechanism of PD reducing the mPAP needs to be further researched and confirmed.

**Icariin**

Icariin (ICA), a typical flavonol glycoside isolated from the Chinese medical herb Epimedium and has been reported to have abundant pharmacological effects, including anti-depressant, anti-inflammation, anti-oxidative stress, heart failure inhibition, cardiovascular protection, and sexual and immune function enhancement. In 2016, Li et al. confirmed that ICA could alleviate the abnormal hemodynamics of the pulmonary artery and right ventricle in PAH model rats induced by MCT, with systolic PAP, diastolic PAP, mPAP, right ventricular systolic pressure, right ventricular diastolic pressure, mean right ventricular pressure reduced, right ventricular preload decreased, compensatory enhancement of right ventricular systolic and diastolic function eased, and right ventricular maximum dP/dt and right ventricular minimum dP/dt absolute value dropped. Furthermore, ICA can slow down the heart rate and prolong the cardiac cycle of PAH model rats. Also, the length of the diastolic period in the cardiac cycle increases gradually following the increase in ICA administration dosage; therefore, it is conducive to improve cardiac function. In addition, ICA treatment is reported to significantly attenuate mPAP, RVH index, and pulmonary artery remodeling, and to decrease the contents of serum angiotensin II, ET, prostaglandine F2α, thromboxane A2, and prostacyclin, and to inhibit the gene expression of angiotensin converting enzyme, cyclooxygenase-2 and thromboxane A2 synthetase. Moreover, Li et al. found that ICA administration could increase the contents of NO and cyclic guanosine monophosphate by improving expression of endothelial NOS and inhibition of 5-type phosphodiesterase in lung tissue of the MCT-injected rats. That is to say, ICA may be effective in protecting against MCT-induced PAH in rats through the increase of NO/cyclic guanosine monophosphate signaling pathway.

**Diterpenoids**

Diterpenoid compounds mostly exist in the form of resins, lactones, or glycosides in nature. Tanshinone compounds and triptolide are the main tricyclic diterpenes that affect PAH.

**Tanshinone IIA**

Tanshinone IIA is a main constituent of *Salvia miltiorrhiza Bge.*, *Salvia sclearea L.*, and *Salvia przewalskii Maxim.* Luo et al. reported that Tanshinone IIA could inhibit cell proliferation and pulmonary vasoconstriction. Furthermore, it can alleviate the downregulation of voltage-gated K⁺ (Kv)1.5 and Kv2.1 in messenger RNA (mRNA) and protein levels induced by chronic hypoxia and upregulate the
level of Kv-mediated currents in PASMCs, which leads to reduced mPAP.\textsuperscript{101} There were also reports that Tanshinone IIA inhibited hypoxia-induced PASMC proliferation through arresting the cells in the G1/G0-phase by slowing down the degradation of p27 via protein kinase B/S-phase kinase associated protein 2-associated pathway.\textsuperscript{102} Meanwhile, Tanshinone IIA inhibits the binding of non-canonical nuclear factor-κB and activator protein-1 to DNA, thus suppressing tumor necrosis factor (TNF)-α-mediated migration of SMCs.\textsuperscript{103}

Sodium Tanshinone IIA Sulfonate is a water-soluble derivative of Tanshinone IIA. Wang et al. have identified that Sodium Tanshinone IIA Sulfonate exerts promising effects on treating PH,\textsuperscript{104} including lowering mean right ventricular systolic pressure, and relieving RVH and pulmonary arterial wall thickness.\textsuperscript{105} In addition, it is well-known that intracellular Ca\textsuperscript{2+} plays a crucial role in the complex mechanisms of VSMC contraction and proliferation. Store-operated calcium channel (SOCC) is mainly composed of canonical transient receptor potential superfamily members and the expression of transient receptor potential superfamily member 1.6 are upregulated selectively by chronic hypoxia. Recently, studies indicated that the upregulation of SOCC induced by hypoxia is the main reason for the imbalance of calcium ions in SMCs. Consequently, the results indicate that Sodium Tanshinone IIA Sulfonate reduces SOCC-mediated store-operated Ca\textsuperscript{2+} entry (SOCE) by inhibiting the chronic hypoxia-induced expression upregulation of transient receptor potential superfamily member 1.6 in remote PASMCs of rat.\textsuperscript{105} Thus, it lowers the concentration of intracellular calcium, dilates pulmonary vasculature, and decreases mPAP.\textsuperscript{106}

**Triptolide**

Triptolide is the active component of TCM *Tripterygium wilfordii* Hook. F., which exhibits a variety of pharmacological effects, such as anti-inflammatory and immune suppression.\textsuperscript{107,108} Research shows that Triptolide can alleviate the development of PH and RVH, and promote regression of pulmonary arterial neointimal formation, possibly through the inhibition of matrix metalloproteinases activity.\textsuperscript{109–111} Moreover, it attenuates the development of PH and RVH in rats receiving MCT injection. Effects on the expressions of matrix metalloproteinases-9 and tissue inhibitor of metalloproteinase-1 may play an important role in facilitating the regression of vascular remodeling.\textsuperscript{112} Furthermore, it also can improve the early inflammatory infiltration of PAH and reduce inflammation reaction. In addition, Triptolide may improve the MCT-induced PAH by inhibiting cell proliferation and inducing apoptosis.\textsuperscript{113}

**Pyranooumarins**

Pyranooumarin compounds are widely found in the plant kingdom, especially in angiosperms such as *Umelliferae*, *Rutaceae*, *Leguminosae*, etc., with biological activities of anti-acquired immunodeficiency syndrome, anti-tumor, and cardiovascular disease treatment.\textsuperscript{104,105}

**Praeruptorin A**

*Peucedanum Praeruptorum Dunnon*, a well-known TCM, is mainly used for the treatment of respiratory diseases in people. In the 1980s and 1990s, Wang et al. found that *Peucedanum Praeruptorum Dunnon* and its extracts had therapeutic effects on PAH animals. Not only can they reduce mPAP and ameliorate pulmonary circulation of a PAH animal model, but they can also suppress pulmonary inflammation.\textsuperscript{106,107} The following studies demonstrated that *Peucedanum Praeruptorum Dunnon* can reduce mPAP without influencing the systemic artery pressure and can decrease the right heart index and thickness of small pulmonary artery media significantly. It was also reported that the composition of tenascin-C decreased significantly in pulmonary vasculature of rats upon treatment with *Peucedanum Praeruptorum Dunnon*.\textsuperscript{108} Several angular-type pyranocoumarins, such as Praeruptorin A, B, C, D, and E, have been identified as the main components of *Peucedanum Praeruptorum Dunnon*.\textsuperscript{109} Among them, Praeruptorin A is considered to be the bioactive component, which showed relaxant effect on ex vivo pulmonary arteries.\textsuperscript{110}

It is well accepted that chronic hypoxia increases the basic calcium concentration of PASMCs in both hypoxia PH rats and cell models. SOCC-induced SOCE enhancement is the main reason for the imbalance of intracellular Ca\textsuperscript{2+} concentration.\textsuperscript{111–113} Previous studies reported that Praeruptorin A could significantly decrease the enhancement of basal Ca\textsuperscript{2+} and SOCE in distal PASMCs of rat, which might suppress cell proliferation and improve PAH.\textsuperscript{114}

Also, the expression and function reduction of the potassium channel, especially the voltage-dependent K\textsuperscript{+} channel causes a series of pulmonary vascular pathological changes in the pathogenesis of PAH. Particularly, abnormal expression and function of Kv 1.5 and Kv 2.1 channel are key factors for PASMC proliferation and apoptosis, which ultimately lead to pulmonary vascular remodeling.\textsuperscript{115,116} Furthermore, it was confirmed that Praeruptorin A obviously suppressed the downregulation of Kv 1.5 and Kv 2.1 mRNA expression caused by hypoxia in rats PASMCs, which may maintain the balance of cell membrane potential, consequently inhibiting cell proliferation and ameliorating PAH.\textsuperscript{117}

**Stilbenes**

The stilbene compound is a general term for a class of substances which have a polystyrene nucleus or a polymer thereof. Stilbene compounds have a variety of biological activities. In addition to the already known antibacterial effects, in recent years it has been found that some stilbene
compounds possess lipid-lowering, expansion of coronary blood vessels and inhibition of platelet aggregation, and anti-hypertensive and anti-tumor effects.\textsuperscript{118}

**Resveratrol**

Resveratrol (RES) is a kind of polyphenol mainly derived from *polygonum cuspidatum*, *Arachis hypogaea Linn*, *Fructus Mori*, and *Vitis vinifera L*. It exists free-form or as a corresponding glycoside in two geometric isomers: cis- (Z) and trans- (E), both of which have anti-oxidative activity.\textsuperscript{119} RES is a new type of compound which can protect ECs and show antioxidiant and anti-inflammatory effects on systemic circulatory system.\textsuperscript{120} Furthermore, it can be used for the prevention and treatment of a variety of cardiovascular diseases, including PH.\textsuperscript{121}

Recently, Chen et al. confirmed that RES, the deglycosylation form of polydatin, could prevent hypoxia-induced human PASMC proliferation and attenuate RVH through the phosphoinositide 3 kinase -protein kinase B signaling pathway.\textsuperscript{122} It was also suggested that resveratrol could improve endothelial function, attenuate oxidative stress, and inhibit inflammatory reaction, while suppressing vascular reconstruction in MCT-induced PAH rats. RES also alleviates mPAP by controlling the proliferation of SMCs and the vascular remodeling.\textsuperscript{123} Accordingly, RES achieves the purpose of prevention and treatment of PAH by playing a vasodilation role.

Moreover, anti-inflammatory effects of RES may be associated with lower expression of inflammatory factors such as interleukins and TNF-\textit{x}.\textsuperscript{124} Studies have shown that monocyte chemoattractant protein-1 (MCP-1) recruits huge amounts of inflammatory cells for the injured part after ALI to form positive feedback.\textsuperscript{125} At the same time, a series of inflammation-related mediators are generated to cause pulmonary vascular EC damage and mPAP increase.\textsuperscript{126} RES significantly decreases the mRNA and protein levels of MCP-1. It suggests that RES can reduce the recruitment of monocytes and alleviate the injury of PAECs caused by inflammatory cells and inflammatory mediators. Previous studies have demonstrated that p38-mitogen-activated protein kinases is the key upstream molecule to generate MCP-1. Experimental results have also revealed that RES suppresses the expression of MCP-1 mainly by limiting the activation of p-p38-mitogen-activated protein kinases. Hence, those effects of RES mitigate PAH eventually.\textsuperscript{127}

**Other natural products**

**Semen lepidii**

Semen lepidii, the seeds of *Descureania Sophia (L)*, have been used in TCM to relieve cough, prevent asthma, reduce edema, and promote urination.\textsuperscript{128} Studies have shown that the compound capsule of *Semen lepidii* evidently decreases rabbit PH induced by 5-hydroxytryptamine in vivo and increases the contraction amplitude of myocardial, that is, enhances myocardial contractility.\textsuperscript{129} So it seems that *Semen lepidii* have effects of improving cardiac output and lowering mPAP and PVR.\textsuperscript{130} Furthermore, it is observed that *Semen lepidii* can improve arterial blood gas in PAH rats.\textsuperscript{131}

Mustard glucoside and G-sitosterol, the active ingredients of *Semen lepidii*, can relieve cough, relax bronchial smooth muscle, and remit bronchial spasm. Moreover, research has found that the Hvitetivoside of *Semen lepidii* distinctly decreases MCT-induced right ventricular systolic and diastolic blood pressure, as well as mPAP.\textsuperscript{132}

**Radix Astragali**

Radix Astragali, the traditional Chinese herb, is the root of *Astragalus membranaceus (Fisch) Bge.*, *Astragalus membranaceus (Fisch) Bge. var. Mongholicus (Bge.) Hsiao*, which has been used as folk herbal medicine in China for many years. Several experimental and clinical studies have provided evidence of its extensive pharmacological effects, including regulating blood pressure and treating nervous, respiratory, and endocrine diseases.\textsuperscript{133}

Although accumulative data have shown that *Radix Astragal* was beneficial for the treatment of PAH,\textsuperscript{134} its mechanisms were multifaceted, and mainly included the following: (1) inhibition of the remodeling of intra-acinar pulmonary arteries and the hyperplasia of collagen;\textsuperscript{135} (2) decrease in the content of ET-1 and increase in the content of NO, improving the expression level of NOS, maintaining the balance of NO/ET-1;\textsuperscript{136} (3) intervening with mRNA expression of collagen in right ventricle;\textsuperscript{137} (4) lowering the concentration of thromboxane A2 in pulmonary tissue and reversing the reconstruction of pulmonary vessels;\textsuperscript{138} (5) regulating the concentration of superoxide dismutate and oxygen free radical in pulmonary tissue, preserving pulmonary vasculature from hypoxia stimulation by the action of antioxidant;\textsuperscript{139} and (6) exerting impact on the other of vaso-active substances.\textsuperscript{140}

**Perspectives**

With the clinical efficacy of natural plant products being fully confirmed from years of practice, they have received more recognition and attention from the international pharmaceutical industry. Proved by numerous studies, natural plant products such as TET have great potential in the treatment of PAH. There are numerous advantages of natural plant products. They are green and with lower economic costs compared with chemical drugs. Natural product treatment is a multi-target and multi-link system with a unique advantage in the therapy of complex diseases, while chemical drugs are primarily for a single target. Meanwhile, some natural plant products exhibit selective functions on pulmonary circulation with no significant effect on system circulation. Hence, there is a good prospect...
and potential development value for natural plant products in PAH therapy.

From the literature reported so far, we summarize the achievements of this field in PAH. (1) Pre-clinical studies and traditional clinical practices have revealed that a number of natural plant products, such as tetradrine, ligustrazine, salidroside, etc., harbor potential in PAH therapy. (2) Some natural plant products, such as ligustrazine, Qingning oral solution, Astragalus, etc., show selective effects in pulmonary circulation and cardiac function. (3) Multiple mechanisms have been involved in the treatment of PAH by natural plant products. For example, Rhodiola inhibits the secretion of ET-1 and promotes the synthesis and release of NO from PAECs, while ligustrazine has an antagonistic effect of Ca$^{2+}$.

However, these studies are preliminary and have limitations. (1) Some natural products can reduce systemic blood pressure and even cause hypotensive reactions. (2) Generally, the effects of nature plant products are weaker than chemical medicines in PAH treatment; they are reasonably compatible and doses should be considered seriously. (3) Experimental and clinical studies with large numbers of subjects are still insufficient to form treatment standards in the utilization of nature plant products. (4) Some plants are reported as showing toxicity in systemic and pulmonary vasculature, such as MCT, Ergotamine, and pyrrolizidine alkaloids contained in the Senecio and Crotalaria plants. The multifunction of natural plant products should be considered carefully.

In summary, natural products have great potential in the treatment of PAH, but the specific mechanisms need further study. We are looking forward to the next efficient medicine for PAH treatment. We also believe that natural products have broad prospects and great value in the future.

**Conflict of interest**

The authors declare that there is no conflict of interest.

**Funding**

This work was supported by National Natural Science Foundation of China (grant no. 81503071 to Y Li, grant no. 81773734 to XH Li) and the 2016 Annual Postgraduate Innovation Program of Central South University (grant no. 2016zzts497 to LL Xiang).

**References**

1. McLaughlin VV and McGoon MD. Pulmonary arterial hypertension. *Circulation* 2006; 114: 1417–1431.
2. Tuder RM, Archer SL, et al. Relevant issues in the pathology and pathobiology of pulmonary hypertension. *J Am Coll Cardiol* 2013; 62: 4–12.
3. Lau EM, Tamura Y, McGoon MD, et al. The 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: a practical chronicle of progress. *Eur Respir J* 2015; 46: 879–882.
4. Badesch DB, Champion HC, Sanchez MA, et al. Diagnosis and assessment of pulmonary arterial hypertension. *J Am Coll Cardiol* 2009; 54: 55–66.
5. Bourji KI and Hassoun PM. Right ventricle dysfunction in pulmonary hypertension: mechanisms and modes of detection. *Curr Opin Pulm Med* 2015; 21: 446–453.
6. Calcutteea A, Lindqvist P, Soderberg S, et al. Global and regional right ventricular dysfunction in pulmonary hypertension. *Echocardiography* 2014; 31: 164–171.
7. Voswinckel R, Reichenberger F, Enke B, et al. Acute effects of the combination of sildenafil and inhaled treprostinil on haemodynamics and gas exchange in pulmonary hypertension. *Palm Pharmacol Ther* 2008; 21: 824–832.
8. Hooper MM, Barberà JA, Channick RN, et al. Diagnosis, assessment, and treatment of non–pulmonary arterial hypertension pulmonary hypertension. *J Am Coll Cardiol* 2009; 54: 85–96.
9. McLaughlin VV, Shah SJ, Souza R, et al. Management of pulmonary arterial hypertension. *J Am Coll Cardiol* 2015; 65: 1976–1997.
10. Fraidenberg D and Yuan J. Current and future therapeutic targets for pulmonary arterial hypertension. *High Alt Med Biol* 2013; 14: 134–143.
11. Chan SY and Lascalzo J. Pathogenic mechanisms of pulmonary arterial hypertension. *J Mol Cell Cardiol* 2008; 44: 14–30.
12. Gomez–Arroyo JG, Farkas L, Alhussaini AA, et al. The monocrotaline model of pulmonary hypertension in perspective. *Am J Physiol Lung Cell Mol Physiol* 2012; 302: 363–369.
13. Bai YJ, Yu M, Zhao SY, et al. Study on pharmacological effect and mechanism of alkaloids (in Chinese). *Journal of Harbin University of Commerce (Natural Sciences Edition)* 2013; 29: 8–11.
14. Meng QM, Liang J, Wu GF, et al. Advances in pharmacological studies of alkaloids compounds (in Chinese). *Lishizhen Med Mater Med Res* 2003; 14: 700–702.
15. Zhao N, Gao F, Liu B, et al. Research advance on the pharmacological effects of benzyltetrahydroisoquinolines alkaloids (in Chinese). *J Pharm Pract* 2015; 33: 313–315.
16. Cao WB, Zeng ZP, Zhu YJ, et al. Effects of tetramethylpyrazine, a Chinese medicine, on plasma endothelin–1 levels during acute pulmonary hypoxia in anesthetized dogs. *J Cardiovasc Pharmoc 1998; 31: 456–459.
17. Feng EZ, Yang SY, Huang NX, et al. Plasma endothelin–1 and nitric oxide correlate with ligustrazine alleviation of pulmonary artery hypertension in patients of chronic cor pulmonale from high altitude plateau during acute exacerbation (in Chinese). *Zhongguo Ying Yong Sheng Li Xue Za Zhi* 2014; 30: 532–537.
18. Cai XX, Chen Z, Pan XK, et al. Inhibition of angiogenesis, fibrosis and thrombosis by tetramethylpyrazine: mechanisms contributing to the SDF–1/CXCR4 axis. *PLoS One* 2014; 9: 1–9.
19. Li M, Handsa S, Ikeda Y, et al. Specific inhibiting characteristics of tetramethylpyrazine, one of the active ingredients of the Chinese herbal medicine ‘Chuanxiong’, on platelet thrombus formation under high shear rates. *Thromb Res* 2001; 104: 15–28.
20. Zhao YK, Liu Y and Chen KJ. Mechanisms and clinical application of tetramethylpyrazine (an interesting natural compound isolated from Ligusticum Wallichii): current status and perspective. *Oxid Med Cell Longev* 2016; 2016: 1–9.
21. Zhang L, Deng M and Zhou S. Tetramethylpyrazine inhibits hypoxia–induced pulmonary vascular leakage in rats via the ROS–HIF–VEGF pathway. *Pharmacology* 2011; 87: 265–273.
22. Guo M, Liu Y and Shi DZ. Cardiovascular actions and therapeutic potential of tetramethylypyrazine (active component isolated from Rhizoma Chuanxiong): roles and mechanisms. *Biomed Res Int* 2016; 2016: 1–9.

23. Pang PK, Shan JJ and Chiu KW. Tetramethylypyrazine, a calcium antagonist. *Planta Med* 1996; 62: 431–435.

24. Xie QM, Tang HF, Chen JQ, et al. Pharmacological actions of tetrandrine in inflammatory pulmonary diseases. *Acta Pharmacol Sin* 2002; 23: 1107–1113.

25. Wei GL and Wang F. Research progress on pharmacological effect of tetrandrine (in Chinese). *J Shanxi Coll Tradit Chin Med* 2004; 27: 66–68.

26. Qi F and Wu NS. Experiment study of tetrandrine on pulmonary artery hypertension in rats (in Chinese). *Heilongjiang Med J* 2010; 34: 737–741.

27. Qi F, Ma DL, Liu SJC, et al. Comparative study of tetrandrine with nifedipine effects on pulmonary arterial hypertension in rats (in Chinese). *J Cardiovascular Pulmonary Dis* 2014; 33: 473–441.

28. Wang HL, Kilfeather SA, Martin GR, et al. Effects of tetrandrine on growth factor–induced DNA synthesis and proliferative response of rat pulmonary artery smooth muscle cells. *Pulm Pharmacol Ther* 2000; 13: 53–60.

29. Meng H, Zhang DR, Song M, et al. Research of expression of platelet–derived growth factor A, B in inhibitory processes of tetrandrine on pulmonary hypertension in rats (in Chinese). *J Cardiovascular Pulmonary Dis* 2000; 29: 10–12.

30. Wang XW, Yang YC, Yang DP, et al. Tetrandrine prevents monocrotaline-induced pulmonary arterial hypertension in rats through regulation of the protein expression of inducible nitric oxide synthase and cyclic guanosine monophosphate–dependent protein kinase type 1. *J Vasc Surg* 2015; 64: 1468–1477.

31. Wang HL, Zhang XH and Chang TH. Effects of tetrandrine on smooth muscle contraction induced by mediators in pulmonary hypertension. *Acta Pharmacol Sin* 2002; 23: 1114–1120.

32. Li FQ and Lu B. The research progress of tetrandrine resistance to pulmonary hypertension (in Chinese). *China Pharmacist* 2000; 3: 77–79.

33. Kumar S and Pandey AK. Chemistry and biological activities of flavonoids: an overview. *ScientificWorldJournal* 2013; 2013: 162750.

34. Pietta PG. Flavonoids as antioxidants. *J Nat Prod* 2000; 63: 1035–1042.

35. Romano B, Pagano E, Montanaro V, et al. Novel insights into the pharmacology of flavonoids. *Phytother Res* 2013; 27: 1588–1596.

36. Xiao ZY and Chen DH. Distribution in plant, pharmacological effect and application research of isoflavone compounds (in Chinese). *World Phytomed* 1998; 13: 157–163.

37. Yao BW and Chen W. Research advances in the pharmacological effects of Ginkgo biloba leaves (in Chinese). *Zhejiang J Integr Tradit Chin West Med* 2005; 15: 192–193.

38. Lee CY, Yang JJ, Lee SS, et al. Protective effect of Ginkgo biloba leaves extract, EGb761, on endotoxin–induced acute lung injury via a JNK– and protein kinase B–dependent NFκB pathway. *J Agr Food Chem* 2014; 62: 6337–6344.

39. Smith J V and Luo Y. Studies on molecular mechanisms of Ginkgo biloba extract. *Appl Microbiol Biotechnol* 2004; 64: 465–472.

40. Yang H, Xu YJ and Zhang ZX. The effect of Ginkgo biloba on hypoxic pulmonary hypertension and the role of protein kinase C (in Chinese). *Zhonghua Jue He He Xi Zi Za Zhi* 2000; 23: 602–605.

41. Cheng D, Chen W, Yang X, et al. Effects of ginkgo plus on hypoxia pulmonary hypertension in rats (in Chinese). *Hua Xi Yi Ke Da Xue Bao* 1996; 27: 415–417.

42. Ren DC, Du GH and Zhang JT. Protective effect of ginkgo biloba extract on endothelial cell against damage induced by oxidative stress. *J Cardiovasc Pharmacol* 2002; 40: 809–814.

43. Tulsiukar J and Shah ZA. Ginkgo biloba prevents transient global ischemia–induced delayed hippocampal neuronal death through antioxidative and anti–inflammatory mechanisms. *Neurochem Int* 2013; 62: 189–197.

44. Liu KX, Wu WK, He W, et al. Ginkgo biloba extract (EGb 761) attenuates lung injury induced by intestinal ischemia/reperfusion in rats: roles of oxidative stress and nitric oxide. *World J Gastroenterol* 2007; 13: 299–305.

45. Zhou YX, Zhang H and Peng C. Puerarin: a review of pharmacological effects. *Phytother Res* 2014; 28: 961–975.

46. Zhang Z, Lam TN and Zuo Z. Radix Puerariae: an overview of its chemistry, pharmacology, pharmacokinetics, and clinical use. *J Clin Pharmacol* 2013; 53: 787–811.

47. Li JW, Chen P, Guan XQ, et al. Inhibition of Puerarin on pulmonary hypertension in rats with hypoxia and hypercapnia (in Chinese). *Zhongguo Zhong Yao Za Zhi* 2008; 33: 544–549.

48. Jun W, Liang XW, Yu QG, et al. Change of elongation factor 2 in pulmonary hypertension rats and study of interfered with Puerarin (in Chinese). *Chin J Clin Pharmacol* 2015; 31: 536–539.

49. Chen C, Chen C, Wang ZY, et al. Puerarin induces mitochondria–dependent apoptosis in hypoxic human pulmonary arterial smooth muscle cells. *PLoS ONE* 2012; 7: e34181.

50. Darbinyan V, Aslanyan G, Armony A, et al. Clinical trial of Rhodiola rosea L. extract SHR–5 in the treatment of mild to moderate depression. *Nord J Psychiatry* 2007; 61: 343–348.

51. Panossian A, Nikoyan N, Ohanyan N, et al. Comparative study of Rhodiola preparations on behavioral despair of rats. *Phytochemistry* 2008; 15: 84–91.

52. van Diermen D, Marston A, Bravo J, et al. Monoamine oxidase inhibition by Rhodiola rosea L. roots. *World J Gastroenterol* 2004; 64: 1035–1042.

53. Kosanovic D, Tian X, Pak O, et al. Rhodiola: an ordinary plant or a promising future therapy for pulmonary hypertension? A brief review. *Pulm Circ* 2013; 3: 499–506.

54. Darbinyan V, Tkeyan A, Panossian A, et al. Rhodiola rosea in stress induced fatigue—a double blind cross–over study of a standardized extract SHR–5 with a repeated low–dose regimen on the mental performance of healthy physicians during night duty. *Phytochemistry* 2000; 23: 365–371.

55. Kelly GS. Rhodiola rosea: a possible plant adaptogen. *Altern Med Rev* 2001; 6: 293–302.

56. Panossian A, Wikman G and Sarris J. Rosenroot (Rhodiola rosea): Traditional use, chemical composition, pharmacology and clinical efficacy. *Phytomedicine* 2010; 17: 481–493.

57. Kosanovic D, Tian X, Pak O, et al. Rhodiola: an ordinary plant or a promising future therapy for pulmonary hypertension? A brief review. *Pulm Circ* 2013; 3: 499–506.

58. Bai MK, Guo Y, Bian BD, et al. Integripetal rhodiola herb attenuates high altitude-induced pulmonary arterial remodeling and expression of vascular endothelial growth factor in rats (in Chinese). *Zhongguo Zhong Xi Yi Jie He Za Zhi* 2016; 46: 761–766.
environment-induced pulmonary hypertension rats (in Chinese). J Lanzhou Univ (Med Sci) 2011; 37: 1–9.

59. Sharma AK, Linden J, Kron IL, et al. Protection from pulmonary ischemia–reperfusion injury by adenosine A2A receptor activation. Respir Res 2009; 10: 58–66.

60. Huang XY, Zou LZ, Yu XM, et al. Salidroside attenuates chronic hypoxia–induced pulmonary hypertension via adenosine A2a receptor related mitochondria–dependent apoptosis pathway. J Mol Cell Cardiol 2015; 82: 153–166.

61. Chen CG, Tang YH, Deng W, et al. Salidroside blocks the proliferation of pulmonary artery smooth muscle cells induced by platelet–derived growth factor BB. Mol Med Rep 2014; 10: 917–922.

62. Lin SX, Liu YL, Zhao HL, et al. Inhibitory effect of Salidroside on the proliferation of rabbit pulmonary artery smooth muscle cells under hypoxia (in Chinese). Chin J Pathophysiol 2001; 10: 968–970.

63. Huang XY, Fan R, Lu YY, et al. The protective effect of salidroside on cor pulmonale rats induced by chronic hypoxia in normal pressure (in Chinese). Chin Arch Trad Chin Med 2011; 29: 1868–1871.

64. Chen M, Cai H, Yu C, et al. Salidroside exerts protective effects against chronic hypoxia–induced pulmonary arterial hypertension via AMPK alphal–dependent pathways. Am J Transl Res 2016; 8: 12–27.

65. Zhang H, Li C, Kwok ST, et al. A review of the pharmacological effects of the dried root of Polygonum cuspidatum (Hu Zhang) and its constituents. Evid Based Complement Alternat Med 2013; 2013: 208349.

66. Lin YW, Yang FJ, Chen CL, et al. Free radical scavenging activity and antiproliferative potential of Polygonum cuspidatum root extracts. J Nat Med 2010; 64: 146–152.

67. Du QH, Peng C and Zhang H. Polyclatin: a review of pharmacology and pharmacokinetics. Pharm Biol 2013; 51: 1347–1354.

68. Zhao KS, Jin C, Huang X, et al. The mechanism of Polyclatin in shock treatment. Clin Hemorheol Microcirc 2003; 29: 211.

69. Qu HL, Li XY, Wang FY, et al. Effect of Polyclatin on hypoxic pulmonary hypertension (in Chinese). J Binxizheng Med Coll 2004; 27: 328–329.

70. Miao Q, Shi XP, Ye MX, et al. Polyclatin attenuates hypoxic pulmonary hypertension and reverses remodeling through protein Kinase C mechanisms. Int J Mol Sci 2012; 13: 7776–7787.

71. Qiao HL, Chen H, Dong YH, et al. Polyclatin attenuates H2O2–induced oxidative stress via PKC pathway. Oxid Med Cell Longev 2016; 2016: 5139458.

72. Jiang Q, Yi M, Guo QQ, et al. Protective effects of polyclatin on lipopolysaccharide–induced acute lung injury through TLR4–MyD88–NF–kB pathway. Int Immunopharmacol 2015; 29: 370–376.

73. Zhang YS, Zhuang ZX, Meng QH, et al. Polyclatin inhibits growth of lung cancer cells by inducing apoptosis and causing cell cycle arrest. Oncol Lett 2014; 7: 295–301.

74. Pan Y, Wang FM, Qiang LQ, et al. Icariin attenuates chronic mild stress–induced dysregulation of the LHPA stress circuit in rats. Psychoneuroendocrinology 2010; 35: 272–283.

75. Pan Y, Hong Y, Zhang QY, et al. Impaired hypothalamic insulin signaling in CUMS rats: restored by icariin and fluoxetine through inhibiting CRF system. Psychoneuroendocrinology 2013; 38: 122–134.

76. Wu JF, Du J, Xu CQ, et al. Icariin attenuates social defeat–induced down–regulation of glucocorticoid receptor in mice. Pharmacol Biochem Behav 2011; 98: 273–278.

77. Guo J, Li F, Wu Q, et al. Protective effects of icariin on brain dysfunction induced by lipopolysaccharide in rats. Phytotherapy 2010; 17: 950–955.

78. Li B, Duan XH, Xu CQ, et al. Icariin attenuates glucocorticoid insensitivity mediated by repeated psychosocial stress on an ovalbumin–induced murine model of asthma. Int Immunopharmacol 2014; 19: 381–390.

79. Zeng N, Meng XL and Zhang Y. Study on the antioxidative effect of constituents of herba epimedi (in Chinese). China J Chin Mater Med 1997; 1: 46–48.

80. Luo Y, Nie J, Gong QH, et al. Protective effects of icarin against learning and memory deficits induced by aluminum in rats. Clin Exp Pharmacol Physiol 2007; 34: 792–795.

81. Xiao HB, Liu ZK, Lu XY, et al. Icariin regulates PRMT/ADMA/DDAH pathway to improve endothelial function. Pharmacol Rep 2015; 67: 1147–1154.

82. Song YH, Li BS, Chen XM, et al. Ethanol extract from Epimedium brevicornum attenuates left ventricular dysfunction and cardiac remodeling through down–regulating matrix metalloproteinase–2 and -9 activity and myocardial apoptosis in rats with congestive heart failure. Int J Mol Med 2008; 21: 117–124.

83. Zhang YW, Morita I, Shao G, et al. Screening of anti–hypoxia/reoxygenation agents by an in vitro model. Planta Med 2000; 66: 114–123.

84. Liang Q, Wei Y, Chen JI, et al. Variation of medicinal components in a unique geographical accession of horny goat weed Epimedium sagittatum Maxim. (Berberidaceae). Molecules 2012; 17: 13345–13356.

85. Schluesener JK and Schluesener H. Plant polyphenols in the treatment of age–associated diseases: Revealing the pleiotropic effects of icariin by network analysis. Mol Nutr Food Res 2014; 58: 49–60.

86. Li LL, Sun J, Xu CQ, et al. Icariin ameliorates cigarette smoke induced inflammatory responses via suppression of NF–kB and modulation of GR in vivo and in vitro. PLoS One 2014; 9: e102345.

87. Li LS, Liu J, Luo YM, et al. Effects of icariin on hemodynamics of pulmonary arterial hypertension induced by monocrotaline in rats (in Chinese). J Zunyi Med Univ 2016; 39: 229–232.

88. Li LS, Luo YM, Liu J, et al. Effects of Icariin on partial vasoactive substances in monocrotaline–induced pulmonary arterial hypertension rat model (in Chinese). Her Med 2017; 36: 847–852.

89. Koizumi H, Yu J, Hashimoto R, et al. Involvement of androgen receptor in nitric oxide production induced by icariin in human umbilical vein endothelial cells. FEBS Letters 2010; 11: 2440–2444.

90. Koizumi H, Yu J, Hashimoto R, et al. Involvement of androgen receptor in nitric oxide production induced by icariin in human umbilical vein endothelial cells. FEBS Letters 2010; 11: 2440–2444.

91. Zheng LH, Liu ML, Wei M, et al. Tanshinone IIA attenuates hypoxia–induced pulmonary arterial hypertension via modifying K+ currents. Respir Physiol Neurobiol 2015; 205: 120–128.

92. Luo Y, Xu DQ, Dong HY, et al. Tanshinone IIA inhibits hypoxia–induced pulmonary artery smooth muscle cell
proliferation via Akt/Skp2/p27-Associated pathway. PLoS One 2013; 8: e56774.

93. Jin UH, Suh SJ, Chang HW, et al. Tanshinone IIA from Salvia miltiorrhiza BUNGE inhibits human aortic smooth muscle cell migration and MMP-9 activity through AKT signaling pathway. J Cell Biochem 2008; 104: 15–26.

94. Wang J, Lu WJ, Wang W, et al. Promising therapeutic effects of sodium tanshinone IIA sulfonate towards pulmonary arterial hypertension in patients. J Thorac Dis 2013; 5: 169–172.

95. Wang J, Jiang Q, Wan LM, et al. Sodium tanshinone IIA sulfonate inhibits canonical transient receptor potential expression in pulmonary arterial smooth muscle from pulmonary hypertensive rats. Am J Respir Cell Mol Biol 2013; 48: 125–134.

96. Huang YF, Liu ML, Dong MQ, et al. Effects of sodium tanshinone IIA sulfonate on hypoxic pulmonary hypertension in rats in vivo and on Kv2.1 expression in pulmonary artery smooth muscle cells in vitro. J Ethnopharmacol 2009; 125: 436–443.

97. Ziaei S and Halaby R. Immunosuppressive, anti-inflammatory and anti-cancer properties of triptolide: A mini review. Avicenna J Phytomed 2016; 6: 149–164.

98. Wang Q, Meng J, Dong AG, et al. The pharmacological effects and mechanism of Tripterygium wilfordii Hook F in central nervous system autoimmunity. J Altern Complement Med 2016; 22: 496–502.

99. Faull JL, Nishimura T, Berry GJ, et al. Triptolide attenuates pulmonary arterial hypertension and neointimal formation in rats. Am J Respir Crit Care Med 2000; 162: 2252–2258.

100. Wei L, Liu T, Liu B, et al. Effect of triptolide on the development of monocrotaline-induced pulmonary hypertension in pneumonectomized rat (in Chinese). Sichuan Da Xue Xue Bao Yi Xue Ban 2007; 5: 806–809.

101. Wei L, Liu T, Liu B, et al. Effect of triptolide on the expression of matrix metalloproteinases 2 and 9 in lungs of experimental pulmonary hypertension (in Chinese). Zhongguo Dang Dai Er Ke Za Zhi 2007; 5: 479–483.

102. Wei L, Liu T, Liu B, et al. Effect of triptolide on the expression of MMP9/TIMP-1 in the lung of expression pulmonary hypertension (in Chinese). Sichuan Med J 2007; 28: 828–830.

103. Wei L, Liu T, Wang XM, et al. Effects of triptolide on anti-proliferation and the enhancement of apoptosis in pulmonary arterial smooth muscle from pulmonary arterial hypertension (in Chinese). Chin Circ J 2006; 21: 473.

104. Cheng G and Xu GB. Advances in pharmacological effects of pyranocoumarin compounds (in Chinese). Chin Trad Pat Med 2013; 35: 1288–1291.

105. Zuo JF, Guo ZJ and Li JS. Pharmacological research progress of pyranocoumarin compounds (in Chinese). Chin Med Mat 2003; 26: 686–689.

106. Rong Z, Wang HL, Zhang XH, et al. Effects of Peucedanum Dunn on hemorhheology and hemodynamics in pulmonary circulation of pulmonary hypertensive rats (in Chinese). J Chin Med Univ 2001; 30: 325–327.

107. Rong Z, Wang HL and Zhang XH. Effects of PPD on hemorhheology, hemodynamics of pulmonary circulation and correlation analysis in pulmonary hypertension in rats (in Chinese). Chin J Mod Appl Pharm 2001; 18: 263–266.

108. Wang JY, Wang HL and Zhang XH. Effects of Peucedanum Praeruptorum Dunn on the monocrotaline-induced pulmonary hypertension in rats (in Chinese). Chin Pharm J 2000; 35: 90–93.

109. Sarkhail P, Shafiee A and Sarkheil P. Biological activities and pharmacokinetics of Praeruptorins from Peucedanum species: a systematic review. Biomed Res Int 2013; 2013: 343808.

110. Zhao NC, Jin WB, Zhang XH, et al. Relaxant effects of Pyranocoumarin compounds isolated from isolated from a Chinese medical plant, Bai-Hua Qian-Hu, on Isolated rabbit tracheas and pulmonary arteries. Biol Pharm Bull 1999; 22: 984–987.

111. Shimoda LA, Wang J and Sylvester JT. Ca^{2+} channels and chronic hypoxia. Microcirculation 2006; 13: 657–670.

112. Wang J, Shimoda LA and Sylvester JT. Capacitative calcium entry and TRPC channel proteins are expressed in rat distal pulmonary arterial smooth muscle. Am J Physiol Lung Cell Mol Physiol 2004; 286: 848–858.

113. Wang J, Weigand L, Lu WJ, et al. Hypoxia inducible factor 1 mediates hypoxia-induced TRPC expression and elevated intracellular Ca^{2+} in pulmonary arterial smooth muscle cells. Circ Res 2006; 98: 1528–1537.

114. Xu L, Zhang M and Fu XH. Effect of Pd–Ia on intracellular calcium concentration in rat pulmonary arterial smooth muscle cells (in Chinese). Int J Respir 2015; 35: 1004–1007.

115. Bonnet S and Archer SL. Potassium channel diversity in the pulmonary arteries and pulmonary veins: implications for regulation of the pulmonary vasculature in health and during pulmonary hypertension. Pharmacol Ther 2007; 115: 56–69.

116. Wang J, Weigand L, Wang WQ, et al. Chronic hypoxia inhibits Kv channel gene expression in rat distal pulmonary artery. Am J Physiol Lung Cell Mol Physiol 2005; 288: 1049–1058.

117. Xiong LQ, Deng HP and Xiao YP. Effect of Pd–Ia on hypoxia–induced expression of Kv 1.5 and Kv 2.1 in rat pulmonary arterial smooth muscle cells (in Chinese). Guangdong J Med 2015; 36: 3119–3122.

118. Chen L and Chen JB. A review of pharmacological research on Súlbene compounds (in Chinese). Guangdong Pharm J 2005; 15: 84–86.

119. Malhotra A, Bath S and Elbarbry F. An organ system approach to explore the antioxidative, anti-inflammatory, and cytoprotective actions of Resveratrol. Oxid Med Cell Longev 2015; 2015: 803971.

120. Labinsky N, Csizsár A, Veress G, et al. Vascular dysfunc- tion in aging: potential effects of resveratrol, an anti-inflammat- oatory and anti-cancer properties of triptolide: A mini review. Avicenna J Phytomed 2016; 6: 149–164.
125. Itoh T, Nagaya N, Ishibashi-Ueda H, et al. Increased plasma monocyte chemoattractant protein–1 level in idiopathic pulmonary arterial hypertension. *Respirology* 2006; 11: 158–163.

126. Park JES, Lyon AR, Shao DM, et al. Pulmonary venous hypertension and mechanical strain stimulate monocyte chemoattractant protein–1 release and structural remodelling of the lung in human and rodent chronic heart failure models. *Thorax* 2014; 69: 1120–1127.

127. Chen C, Wang Y, Cai XD, et al. Resveratrol downregulates acute pulmonary thromboembolism–induced pulmonary artery hypertension via p38 mitogen–activated protein kinase and monocyte chemoattractant protein–1 signaling in rats. *Life Sci* 2012; 90: 721–727.

128. Lee YJ, Kim NS, Kim H, et al. Cytotoxic and anti-inflammatory constituents from the seeds of Descurainia sophia. *Arch Pharm Res* 2013; 36: 536–541.

129. Bai ZP, Zheng B, Bu XC, et al. Research on the effect of compound capsule of Semen Lepidii on pulmonary artery hypertension and myocardial contractility (in Chinese). *J Tradit Chin Med* 1997; 18: 531.

130. Xiong XD, Wang Z. The compound injection of Semen Lepidii in the treatment of senile cor pulmonale with acute heart failure 60 cases (in Chinese). *Shanxi J Tradit Chin Med* 1997; 4: 73–74.

131. Ren S, Zhang H, Mu Y, et al. Pharmacological effects of Astragaloside IV: a literature review. *J Tradit Chin Med* 2013; 33: 413–416.

132. Xi SC, Ruan YM, Liu YH, et al. The inhibitory effects of Radix Astragali on hypoxic pulmonary hypertension of rats (in Chinese). *Chin Med J (Engl)* 1998; 111: 956–958.

133. Xi SC, Ruan YM, Liu YH, et al. Morphometric investigation on hypoxic structural remodelling of intracinar pulmonary arteries (in Chinese). *Zhonghua Jie He He Hu Xi Za Zhi* 1998; 21: 303–305.

134. Liu JC, An CS, Wang JF, et al. Influence of Radix Astragali on nitric oxide and endothelin–1 in pulmonary tissue in hypoxic pulmonary hypertension in rats (in Chinese). *Zhonghua Er Ke Za Zhi* 2006; 44: 46–48.

135. He JG, Jing ZC, Gu Q, et al. Collagen expression of intracinar pulmonary arteries and right ventricle and intervention of Radix Astragali in rats with hypoxic pulmonary hypertension (in Chinese). *Natl Med J China* 1999; 79: 654.

136. An CS, Liu JC, Piao HM, et al. Effects of Radix Astragali on remodeling of intracinar pulmonary arteries and TXA2 in hypoxic pulmonary hypertension in rats (in Chinese). *Liaoning J Tradit Chin Med* 2007; 34: 1641–1642.

137. Liu JC, An CS, Yan CH, et al. Influence of Radix Astragali on superoxide dismutase and malondialdehyde in pulmonary tissue of hypoxic pulmonary hypertension in rats (in Chinese). *J Med Sci Yanbian Univ* 2002; 25: 97–100.

138. Tang JY and Sun CQ. Curative effect of Astragalus injection for pulmonary artery hypertension of patients with pneumo-cardiac disease (in Chinese). *Mod J Integr Tradit Chin West Med* 2003; 12: 32.

139. Egermayer P. Epidemics of vascular toxicity and pulmonary hypertension: what can be learned? *J Intern Med* 2000; 87: 11–17.

140. Bach N, Thung SN and Schaffner F. Comfrey herb tea-induced hepatic veno-occlusive disease. *Am J Med* 1989; 87: 97–99.

141. Liang D, Wang X, Gong H, et al. Ginkgo suppresses atherosclerosis through downregulating the expression of connexin 43 in rabbits. *Arch Med Sci* 2013; 9: 340–346.

142. Lim S, Yoon JW, Kang SM, et al. EGB761, a Ginkgo biloba extract, is effective against atherosclerosis in vitro, and in a rat model of type 2 diabetes. *PLoS One* 2011; 6: e20301.

143. Chen JS, Huang PH, Wang CH, et al. Nrf-2 mediated heme oxygenase-1 expression, an antioxidant-independent mechanism, contributes to anti-atherogenesis and vascular protective effects of Ginkgo biloba extract. *Atherosclerosis* 2011; 214: 301–309.

144. Rodriguez M, Ringstad L, Schäfer P, et al. Reduction of atherosclerotic nanoplaque formation and size by Ginkgo biloba (EGB 761) in cardiovascular high-risk patients. *Atherosclerosis* 2007; 192: 438–444.

145. Fang ZY, Lin R, Yuan BX, et al. Tanshinone IIA inhibits atherosclerotic plaque formation by down-regulating MMP-2 and MMP-9 expression in rabbits fed a high-fat diet. *Life Sci* 2007; 81: 1339–1345.

146. Chen Z and Xu H. Anti-inflammatory and immunomodulatory mechanism of Tanshinone IIA for atherosclerosis. *Evid Based Complement Alternat Med* 2014; 2014: 267976.

147. Chen WY, Tang FT, Xie BL, et al. Amelioration of atherosclerotic plaque formation by down-regulating MMP-2 and MMP-9 expression in rabbits fed a high-fat diet. *Life Sci* 2007; 81: 1339–1345.

148. Minatti J, Wazlawik E, Hort MA, et al. Green tea extract, is effective against atherosclerosis in vitro, and in a rat model of type 2 diabetes. *Atherosclerosis* 2007; 214: 427–438.

149. Cai Y, Kurita-Ochiai T, Hashizume T, et al. Green tea epigallocatechin-3-gallate attenuates Porphyromonas gingivalis-induced atherosclerosis. *Pathog Dis* 2013; 67: 76–83.

150. Yin JG, Huang F, Yi YH, et al. EGCG attenuates atherosclerosis through the Jagged-1/Notch pathway. *Int J Mol Med* 2016; 37: 398–406.

151. You Y, Duan Y, Liu SW, et al. Anti-atherosclerotic function of Astragalus Radix extract: downregulation of adhesion molecules in vitro and in vivo. *BMC Complement Altern Med* 2012; 12: 54.

152. Wang DQ, Zhuang Y, Tian YP, et al. Study of the effects of total flavonoids of Astragalus on atherosclerosis formation and potential mechanisms. *Oxid Med Cell Longev* 2012; 2012: 282383.

153. Qin HW, Liu P and Lin SC. Effects of Astragaloside IV on the SDF-1/CXCR4 expression in atherosclerosis of apoE(-/-)
172. Yao Y, Wu WY, Liu AH, et al. Interaction of salvianolic acids and notoginsenosides in inhibition of ADP-induced platelet aggregation. *Biochem Mol Biol Int* 1998; 46: 1243–1248.

159. Kudolo GB, Dorsey S and Blodgett J. Effect of the ingestion of Ginkgo biloba extract on platelet aggregation and urinary prostanoid excretion in healthy and Type 2 diabetic subjects. *Thromb Res* 2002; 108: 151–160.

167. Jin RM, Chen CX, Li YK, et al. Effects of rhynchophylline on platelet aggregation and experimental thrombosis (in Chinese). *J Ethnopharmacol* 2011; 395–402.

184. Ndagijimana A, Wang XM, Pan GX, et al. A review on the pharmacological effects of Rhynchophylline on cardiovascular system (in Chinese). *Science & Technology Vision* 2017; 1: 65–66.

176. Abdel-Zaher AO, Farghaly HSM, El-Refaiy AEM, et al. Protective effect of the standardized extract of ginkgo biloba (EGb761) against hypertension with hypercholesterolemia-induced renal injury in rats: Insights in the underlying mechanisms. *Biomed Pharmacother* 2017; 95: 944–955.

190. DeFeudis FV. Effects of Ginkgo biloba extract (EGb 761) on myocardium injury in Ginkgo biloba leaves extract, EGb761, on myocardium injury in ischemia reperfusion rats via regulation of TLR-4/NF-κB signaling pathway. *Oncotarget* 2017; 8: 86671–86680.

174. Chen X, Salwinski S and Lee TJ. Extracts of Ginkgo biloba and ginsenosides exert cerebral vasorelaxation via nitric oxide pathway. *Clin Exp Pharmacol Physiol* 1997; 24: 958–959.

189. Akdere H, Tastekin E, Mericliler M, et al. The protective effect of the combination of Uncaria and Semen Raphani on vascular endothelium in spontaneously hypertensive rats. *Evid Based Complement Alternat Med* 2015; 2015: 385154.
190. Wang Y, Pei DS, Ji HX, et al. Protective effect of a standardized Ginkgo extract (ginaton) on renal ischemia/reperfusion injury via suppressing the activation of JNK signal pathway. *Phytomedicine* 2008; 15: 923–931.

191. Zhao BL, Jiang W, Zhao Y, et al. Scavenging effects of salvia miltiorrhiza on free radicals and its protection for myocardial mitochondrial membranes from ischemia-reperfusion injury. *Biochem Mol Biol Int* 1996; 38: 1171–1182.

192. Xia WJ, Yang M, Fok TF, et al. Partial neuroprotective effect of pretreatment with tanshinone IIA on neonatal hypoxia-ischemia brain damage. *Pediatr Res* 2005; 58: 784–790.

193. Zhou GY, Jiang W, Zhao Y, et al. Sodium tanshinone IIA sulfonate mediates electron transfer reaction in rat heart mitochondria. *Biochem Pharmacol* 2003; 65: 51–57.

194. Kang BK, Kim MK, Kim SY, et al. Anti-neuroinflammatory effects of Uncaria sinensis in LPS-stimulated BV2 microglia cells and focal cerebral ischemic mice. *Am J Chin Med* 2015; 43: 1099–1115.

195. Hu XY, Sun AS and Sui YX. Effects of combined use of total alkaloids of Uncaria rhynchophylla and Coryadlis ambailismigo on cerebral ischemia-reperfusion injury in rats (in Chinese). *Zhongguo Zhong Xi Yi Jie He Za Zhi* 2007; 27: 1007–1009.

196. Qiao ZY, Ma JW and Liu HJ. Effect of Ligusticum wallichii aqueous extract on oxidative injury and immunity activity in myocardial ischemic reperfusion rats. *Int J Mol Sci* 2011; 12: 1991–2006.

197. Chen SY, Hsiao G, Hwang HR, et al. Tetramethylpyrazine induces heme oxygenase-1 expression and attenuates myocardial ischemic reperfusion injury in rats. *J Biomed Sci* 2006; 13: 731–740.

198. Zhang CB, Teng FM, Tu J, et al. Ultrasound-enhanced protective effect of tetramethylpyrazine against cerebral ischemia/reperfusion injury. *PLoS One* 2014; 9: e113673.

199. Liao SL, Kao TK, Chen WY, et al. Tetramethylpyrazine reduces ischemic brain injury in rats. *Neurosci Lett* 2004; 372: 40–45.

200. Oh JK, Hyun SY, Oh HR, et al. Effects of Anemarrhena asphodeloides on focal ischemic brain injury induced by middle cerebral artery occlusion in rats. *Biol Pharm Bull* 2007; 30: 38–43.